Table 2. Chemotherapy Agents.
| Chemotherapy medication | Frequency of use (% of total patients) |
|---|---|
| Rituximab | 89 (44) |
| Cyclophosphamide | 42 (21) |
| Ibrutinib | 40 (20) |
| Bendamustine | 39 (19) |
| Prednisone | 39 (19) |
| Lenalidomide | 32 (16) |
| Dexamethasone | 29 (14) |
| Vincristine | 25 (12) |
| Bortezomib | 24 (12) |
| Daratumumab | 22 (11) |
| Fludarabine | 20 (10) |
| Adriamycin | 17 (8) |
| Venetoclax | 15 (7) |
| Chlorambucil | 10 (5) |
| Acalabrutinib | 7 (3) |
| Methotrexate | 5 (2) |
| Pomalidomide | 5 (2) |
| Cytarabine | 4 (2) |
| Decitabine | 4 (2) |
| Doxorubicin | 4 (2) |
| Melphalan | 4 (2) |
| Daunorubicin | 3 (1) |
| Obinutuzumab | 3 (1) |
| 6-mercaptopurine | 2 (1) |
| Asparaginase | 2 (1) |
| Cladribine | 2 (1) |
| Elotuzumab | 2 (1) |
| Oxaliplatin | 2 (1) |
| Bosutinib | 1 (0.5) |
| Carfilzomib | 1 (0.5) |
| Cisplatin | 1 (0.5) |
| Dasatinib | 1 (0.5) |
| Docetaxel | 1 (0.5) |
| Epirubicin | 1 (0.5) |
| Fluorouracil | 1 (0.5) |
| Imexon | 1 (0.5) |
| Interferon alpha | 1 (0.5) |
| Ivosidenib | 1 (0.5) |
| Nelarabine | 1 (0.5) |
| Ofatumumab | 1 (0.5) |
| Pembrolizumab | 1 (0.5) |
| Pertuzumab | 1 (0.5) |
| Thalidomide | 1 (0.5) |